Melia W M, Bullock S, Johnson P J, Williams R
Cancer. 1983 Jun 1;51(11):2112-5. doi: 10.1002/1097-0142(19830601)51:11<2112::aid-cncr2820511126>3.0.co;2-6.
The serum ferritin level was raised in 34 of 35 (97%) patients with hepatocellular carcinoma and in 20 of 23 (87%) with uncomplicated cirrhosis. Levels rose following therapeutic embolisation in 14 of 15 patients and continued to rise in 85% of all tumor patients who showed no clinical response to chemotherapy (intravenous Adriamycin) whereas in those who did respond the serum ferritin level fell. By contrast, there was a fall in serum alphafetoprotein immediately after embolisation but like serum ferritin, alphafetoprotein levels rose with disease progression and only fell in those achieving clinical remission. Serum ferritin has no role in the differential diagnosis of hepatocellular carcinoma but may be a useful marker in monitoring response to chemotherapy particularly in the alphafetoprotein-negative patient.
35例肝细胞癌患者中有34例（97%）血清铁蛋白水平升高，23例无并发症肝硬化患者中有20例（87%）血清铁蛋白水平升高。15例患者中有14例在治疗性栓塞后血清铁蛋白水平升高，在所有对化疗（静脉注射阿霉素）无临床反应的肿瘤患者中，85%的患者血清铁蛋白水平持续升高，而有反应的患者血清铁蛋白水平下降。相比之下，栓塞后血清甲胎蛋白立即下降，但与血清铁蛋白一样，甲胎蛋白水平随疾病进展而升高，仅在实现临床缓解的患者中下降。血清铁蛋白在肝细胞癌的鉴别诊断中无作用，但在监测化疗反应方面可能是一个有用的标志物，特别是在甲胎蛋白阴性的患者中。
